BETR, CNTY, ACXP Report Earnings March 13, 2026 em Several com

BETR, CNTY, and ACXP announce Q4 2025 earnings on March 13, 2026. See expected EPS and year-over-year growth.

Several companies are scheduled to release their earnings reports before the market opens on March 13, 2026. This includes Better Home & Finance Holding Company (BETR), Century Casinos, Inc. (CNTY), and Acurx Pharmaceuticals, Inc. (ACXP). Investors will be closely watching these reports for insights into the companies’ financial performance and future outlook.

Imagem
Imagem

Earnings Previews for March 13, 2026

Better Home & Finance Holding Company (BETR) is set to report for the quarter ending December 31, 2025. According to analyst consensus, the earnings per share (EPS) is expected to be $-2.16. This figure represents a 23.13% increase compared to the same quarter in the previous year. In the third quarter of 2025, BETR’s reported EPS fell short of expectations by 4.39%. Industry data indicates that BETR’s 2025 Price to Earnings (P/E) ratio is -4.05, significantly lower than the industry average of 12.20, suggesting potential undervaluation or specific market challenges.

Nasdaq logo
Nasdaq logo, representing financial market data.

Century Casinos, Inc. (CNTY) will also announce its earnings for the quarter ending December 31, 2025. The consensus EPS forecast stands at $-0.46, marking a 33.33% increase year-over-year. The company’s 2025 P/E ratio is reported as -0.77, contrasting sharply with the industry P/E of 19.40. This substantial difference may indicate unique financial dynamics for Century Casinos within the gaming sector.

Acurx Pharmaceuticals Earnings Outlook

Acurx Pharmaceuticals, Inc. (ACXP) is reporting for the quarter ending December 31, 2025, with an anticipated EPS of $-1.01. This represents a significant 68.44% increase from the prior year’s corresponding quarter. Notably, ACXP has exceeded earnings expectations in two of the last four quarters. The company’s 2025 P/E ratio is -1.05, compared to the industry average of -5.60. This suggests that Acurx Pharmaceuticals is projected to experience higher earnings growth than its industry peers.

Fonte: Nasdaq


Images and videos belong to their respective owners.
This content may include information compiled from external sources and produced with the assistance of AI tools under editorial supervision.

Need to adjust credit or request removal? Click here.